| Condensed Balance Sheet [Table Text Block] |
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Current assets | | $ | — | | | $ | — | | | $ | 83,390 | | | $ | 20 | | | $ | 83,410 | |
| Non-current assets | | | — | | | | — | | | | 114,677 | | | | 3,348 | | | | 118,025 | |
| Current liabilities | | | — | | | | — | | | | (126,986 | ) | | | (6,953 | ) | | | (133,939 | ) |
| Non-current liabilities | | | — | | | | — | | | | (31,720 | ) | | | (1,442 | ) | | | (33,162 | ) |
| Net assets | | $ | — | | | $ | — | | | $ | 39,361 | | | $ | (5,027 | ) | | $ | 34,334 | |
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2024 | |
| Current assets | | $ | — | | | $ | 12 | | | $ | 95,720 | | | $ | 3 | | | $ | 95,735 | |
| Non-current assets | | | 32,000 | | | | — | | | | 124,675 | | | | 3,637 | | | | 160,312 | |
| Current liabilities | | | — | | | | (9 | ) | | | (130,945 | ) | | | (6,913 | ) | | | (137,867 | ) |
| Non-current liabilities | | | — | | | | — | | | | (24,482 | ) | | | (1,452 | ) | | | (25,934 | ) |
| Net assets | | $ | 32,000 | | | $ | 3 | | | $ | 64,968 | | | $ | (4,725 | ) | | $ | 92,246 | |
|
| Condensed Income Statement [Table Text Block] |
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Revenue | | $ | — | | | $ | — | | | $ | 78,414 | | | $ | — | | | $ | 78,414 | |
| Total expenses | | | 20,000 | | | | 11 | | | | 54,274 | | | | 290 | | | | 74,575 | |
| Net (loss) income | | | (20,000 | ) | | | (11 | ) | | | 24,140 | | | | (290 | ) | | | 3,839 | |
| Other comprehensive (loss) income | | | — | | | | 8 | | | | (45 | ) | | | (12 | ) | | | (49 | ) |
| Net comprehensive (loss) income | | $ | (20,000 | ) | | $ | (3 | ) | | $ | 24,095 | | | $ | (302 | ) | | $ | 3,790 | |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (6,400 | ) | | | (1 | ) | | | 11,807 | | | | (30 | ) | | | 5,376 | |
| Additional income attributable to NCI | | | — | | | | — | | | | — | | | | — | | | | - | |
| Net comprehensive (loss) income attributable to NCI | | $ | (6,400 | ) | | $ | (1 | ) | | $ | 11,807 | | | $ | (30 | ) | | $ | 5,376 | |
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2024 | |
| Revenue | | $ | — | | | $ | — | | | $ | 103,331 | | | $ | — | | | $ | 103,331 | |
| Total expenses | | | 42,681 | | | | (1,064 | ) | | | 40,935 | | | | (203 | ) | | | 82,349 | |
| Net (loss) income | | | (42,681 | ) | | | 1,064 | | | | 62,396 | | | | 203 | | | | 20,982 | |
| Other comprehensive (loss) income | | | — | | | | (9 | ) | | | 171 | | | | (334 | ) | | | (172 | ) |
| Net comprehensive (loss) income | | $ | (42,681 | ) | | $ | 1,055 | | | $ | 62,567 | | | $ | (131 | ) | | $ | 20,810 | |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (13,658 | ) | | | 264 | | | | 30,658 | | | | (13 | ) | | | 17,251 | |
| Additional income attributable to NCI | | | — | | | | — | | | | 5,336 | | | | — | | | | 5,336 | |
| Net comprehensive (loss) income attributable to NCI | | $ | (13,658 | ) | | $ | 264 | | | $ | 35,994 | | | $ | (13 | ) | | $ | 22,587 | |
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2023 | |
| Revenue | | $ | — | | | $ | 126 | | | $ | 161,453 | | | $ | 1 | | | $ | 161,580 | |
| Total expenses | | | 107,297 | | | | 748 | | | | 85,460 | | | | 57,293 | | | | 250,798 | |
| Net (loss) income | | | (107,297 | ) | | | (622 | ) | | | 75,993 | | | | (57,292 | ) | | | (89,218 | ) |
| Other comprehensive (loss) income | | | 70,778 | | | | (21 | ) | | | (961 | ) | | | (34,643 | ) | | | 35,153 | |
| Net comprehensive (loss) income | | $ | (36,519 | ) | | $ | (643 | ) | | $ | 75,032 | | | $ | (91,935 | ) | | $ | (54,065 | ) |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (11,686 | ) | | | (161 | ) | | | 36,766 | | | | (9,194 | ) | | | 15,725 | |
| Additional income attributable to NCI | | | — | | | | — | | | | 11,421 | | | | — | | | | 11,421 | |
| Net comprehensive (loss) income attributable to NCI | | $ | (11,686 | ) | | $ | (161 | ) | | $ | 48,187 | | | $ | (9,194 | ) | | $ | 27,146 | |
|